News

Mizuho's Jared Holz on what is next for Sarepta after second death connected to gene therapy
Jared Holz, Mizuho, joins 'Fast Money' to talk the fallout for Sarepta after another death related to its muscular dystrophy ...
Sarepta shares crash as second patient dies after receiving its gene therapy
Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...
Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...
Second patient death reported with gene therapy for muscular dystrophy
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...
Sarepta reports second patient death after treatment with Duchenne gene therapy
Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...
Explore more
GlobalData on MSN17h
Sarepta and Roche halt DMD gene therapy’s use after second death
Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.
Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
Sarepta Therapeutics, Inc. stock fell after an ELEVIDYS-related death. However, click for why strong SRTP revenue growth and ...
STAT10h
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...
Business Wire17h
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS ...
Sarepta down analysts flag risks after second Elevidys-linked death
BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular ...